Current Editions
European Parliament chooses middle ground in pharma legislation
After ping-ponging, proposed data exclusivity periods now more in line with current framework
Politics, Policy & Law
Data Byte
Four PDUFA dates coming in May
BMS awaits decisions on two new indications for Breyanzi; therapies from Ascendis, Dynavax also up for approvals
Management Tracks
McDonnell now CEO of Agilent
Plus: Dubensky to lead ImmuneSensor and updates from NORD and Epsilogen
BioCentury ISSN 1097-7201